Login
$KYMR
$125.10 -$2.47 (1.94%) Live

$KYMR SEC Filings

Filed On Filing
29 Oct 2026 10-Q
29 Oct 2026 8-K: Results of Operations and Financial Condition

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial

27 Oct 2026 SCHEDULE 13G/A
01 Oct 2026 Form 4: Mainolfi Nello, Director

Received 30,000 shares by exercise or conversion ($62.4K) · Sold 30,000 shares ($3.41M)

01 Oct 2026 144
08 Sep 2026 SCHEDULE 13G/A
04 Sep 2026 Form 4: Adams Brian, Chief Legal Officer

Sold 6,371 shares ($744K)

04 Sep 2026 144
02 Sep 2026 144
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026

27 Jul 2026 Form 4: Rooney Terence, Chief Medical Officer

Received 38,000 shares as a grant or award · Granted 76,000 Stock Option (Right to Buy)

27 Jul 2026 Form 3: Rooney Terence, Chief Medical Officer

No securities owned

27 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio

07 Jul 2026 Form 4: Mainolfi Nello, Director

Received 50,000 shares by exercise or conversion ($104K) · Sold 50,000 shares ($5.95M)

07 Jul 2026 144
02 Jul 2026 Form 4: Jacobs Bruce N., Chief Financial Officer

Received 61,378 shares by exercise or conversion ($327K) · Sold 77,109 shares ($8.86M)

02 Jul 2026 Form 4: Goodman Noah, Chief Business Officer

Sold 3,389 shares ($387K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support